Maravai Lifesciences Holdings annual r&d spending
2019
2020
2021
2022
2023
2024
2025
Maravai Lifesciences Holdings R&D Spending Growth & History (MRVI)
Maravai Lifesciences Holdings's r&d spending was $17.4M for fiscal 2025.
View full Maravai Lifesciences Holdings company overviewMaravai Lifesciences Holdings annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $17.4M | −$1.8M | −9.46% |
| 2024 | 2024-12-31 | $19.2M | $1.9M | +11.23% |
| 2023 | 2023-12-31 | $17.3M | −$1.1M | −5.93% |
| 2022 | 2022-12-31 | $18.4M | $3.1M | +20.70% |
| 2021 | 2021-12-31 | $15.2M | $5.9M | +63.57% |
| 2020 · Dec 31 | 2020-12-31 | $9.3M | $5.7M | +156.52% |
| 2019 | 2019-12-31 | $3.6M | — | — |
Maravai Lifesciences Holdings quarterly r&d spending
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $3.7M | −$1.2M | −24.17% |
| Q1 2026 | 2026-03-31 | $3.9M | −$999,000 | −20.44% |
| Q4 2025 | 2025-12-31 | $3.8M | −$773,000 | −16.95% |
| Q3 2025 | 2025-09-30 | $3.8M | −$860,000 | −18.28% |
| Q2 2025 | 2025-06-30 | $4.9M | −$42,000 | −0.85% |
| Q1 2025 | 2025-03-31 | $4.9M | −$144,000 | −2.86% |
| Q4 2024 | 2024-12-31 | $4.6M | −$33,000 | −0.72% |
| Q3 2024 | 2024-09-30 | $4.7M | $357,000 | +8.21% |
| Q2 2024 | 2024-06-30 | $4.9M | $730,000 | +17.41% |
| Q1 2024 | 2024-03-31 | $5.0M | $887,000 | +21.40% |
| Q4 2023 | 2023-12-31 | $4.6M | −$417,000 | −8.32% |
| Q3 2023 | 2023-09-30 | $4.3M | −$1.0M | −19.34% |
| Q2 2023 | 2023-06-30 | $4.2M | −$80,000 | −1.87% |
| Q1 2023 | 2023-03-31 | $4.1M | $450,000 | +12.18% |
| Q4 2022 | 2022-12-31 | $5.0M | −$4.2M | −45.44% |
| Q3 2022 | 2022-09-30 | $5.4M | $3.4M | +176.93% |
| Q2 2022 | 2022-06-30 | $4.3M | $2.3M | +121.57% |
| Q1 2022 | 2022-03-31 | $3.7M | $1.5M | +71.06% |
| Q4 2021 | 2021-12-31 | $9.2M | $7.1M | +339.01% |
| Q3 2021 | 2021-09-30 | $1.9M | $78,000 | +4.18% |
| Q2 2021 | 2021-06-30 | $1.9M | $329,000 | +20.56% |
| Q1 2021 | 2021-03-31 | $2.2M | −$1.6M | −42.31% |
| Q4 2020 | 2020-12-31 | $2.1M | — | — |
| Q3 2020 | 2020-09-30 | $1.9M | — | — |
| Q2 2020 | 2020-06-30 | $1.6M | — | — |
| Q1 2020 | 2020-03-31 | $3.7M | — | — |
Maravai Lifesciences Holdings r&d spending trends
Over the last five fiscal years, Maravai Lifesciences Holdings's r&d spending increased from $9.3M to $17.4M, a change of $8.1M. The latest reported quarter, Q2 2026, shows $3.7M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Maravai Lifesciences Holdings source filings ↗